These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 18245819

  • 1. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
    Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zaïr Y, Nguyen P, Krempf M, Cariou B, Costet P.
    J Biol Chem; 2008 Apr 11; 283(15):9666-73. PubMed ID: 18245819
    [Abstract] [Full Text] [Related]

  • 2. In vivo evidence that furin from hepatocytes inactivates PCSK9.
    Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, Seidah NG, Prat A.
    J Biol Chem; 2011 Feb 11; 286(6):4257-63. PubMed ID: 21147780
    [Abstract] [Full Text] [Related]

  • 3. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.
    Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M.
    J Biol Chem; 2006 Mar 10; 281(10):6211-8. PubMed ID: 16407292
    [Abstract] [Full Text] [Related]

  • 4. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.
    Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG.
    J Biol Chem; 2006 Oct 13; 281(41):30561-72. PubMed ID: 16912035
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 9. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, Strack AM, Wang F, Pandit S, Hammond H, Wood D, Lewis D, Rosa R, Mendoza V, Cumiskey AM, Johns DG, Hansen BC, Shen X, Geoghagen N, Jensen K, Zhu L, Wietecha K, Wisniewski D, Huang L, Zhao JZ, Ernst R, Hampton R, Haytko P, Ansbro F, Chilewski S, Chin J, Mitnaul LJ, Pellacani A, Sparrow CP, An Z, Strohl W, Hubbard B, Plump AS, Blom D, Sitlani A.
    Int J Biol Sci; 2012 Oct 15; 8(3):310-27. PubMed ID: 22355267
    [Abstract] [Full Text] [Related]

  • 10. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.
    Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, Costet P, Cariou B.
    FEBS Lett; 2008 Mar 19; 582(6):949-55. PubMed ID: 18298956
    [Abstract] [Full Text] [Related]

  • 11. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
    Lipari MT, Li W, Moran P, Kong-Beltran M, Sai T, Lai J, Lin SJ, Kolumam G, Zavala-Solorio J, Izrael-Tomasevic A, Arnott D, Wang J, Peterson AS, Kirchhofer D.
    J Biol Chem; 2012 Dec 21; 287(52):43482-91. PubMed ID: 23135270
    [Abstract] [Full Text] [Related]

  • 12. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y, Chen Y, Hu W, Li X, Yang X, Zhou X, Yin Z, Kong D, Yao Z, Hajjar DP, Liu L, Liu Q, Han J.
    J Biol Chem; 2012 Jul 06; 287(28):23667-77. PubMed ID: 22593575
    [Abstract] [Full Text] [Related]

  • 13. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
    Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A.
    Arterioscler Thromb Vasc Biol; 2004 Aug 06; 24(8):1454-9. PubMed ID: 15178557
    [Abstract] [Full Text] [Related]

  • 14. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE, Lemieux V, Noad J, Moore JI, Dewpura T, Raymond A, Chrétien M, Figeys D, Mayne J.
    FEBS J; 2015 Jul 06; 282(14):2682-96. PubMed ID: 25913303
    [Abstract] [Full Text] [Related]

  • 15. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
    Dong B, Wu M, Cao A, Li H, Liu J.
    Int J Mol Med; 2011 Jan 06; 27(1):103-10. PubMed ID: 21069265
    [Abstract] [Full Text] [Related]

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
    Awan Z, Baass A, Genest J.
    Clin Chem; 2014 Nov 06; 60(11):1380-9. PubMed ID: 25248569
    [Abstract] [Full Text] [Related]

  • 17. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
    Maxwell KN, Breslow JL.
    Curr Opin Lipidol; 2005 Apr 06; 16(2):167-72. PubMed ID: 15767856
    [Abstract] [Full Text] [Related]

  • 18. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y, Ye J, Li J, Chen C, Huang J, Liu P, Huang H.
    Cardiovasc Diabetol; 2016 Feb 01; 15():19. PubMed ID: 26833058
    [Abstract] [Full Text] [Related]

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.
    Hepatology; 2008 Aug 01; 48(2):646-54. PubMed ID: 18666258
    [Abstract] [Full Text] [Related]

  • 20. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.
    Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chrétien M.
    Lipids Health Dis; 2008 Jun 11; 7():22. PubMed ID: 18547436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.